Elizabeth O'Brien Stenger, MD, MSc
- Assistant Professor of Pediatrics
Administrative Assistant: Karen Pruszynski
Elizabeth Stenger joined the Division of Blood and Marrow Transplantation and Cellular Therapies as an Assistant Professor of Pediatrics in November 2018. She obtained her medical degree from the University of Pittsburgh School of Medicine, followed by pediatric residency and fellowship in both pediatric hematology/oncology and BMT at UPMC Children’s Hospital of Pittsburgh.
Stenger spent five years as faculty at Emory University, where she pursued her research interests in transplant tolerance and developed interests in BMT for sickle cell disease. Her research is funded in part by a K23 Career Development Award through the NHLBI, focusing on using cell therapy to promote tolerance in transplant for non-malignant diseases.
Professional and Scientific Society Memberships
- American Society for Blood and Marrow Transplantation, 2011-Present
- American Society of Hematology, 2012-Present
- Children’s Oncology Group, 2013-Present
- American Society of Pediatric Hematology and Oncology, 2015-Present
- International Society Cell and Gene Therapy, 2016-Present
Education & Training
- BS, Science, University of Notre Dame, 1998-2002
- MD, University of Pittsburgh, 2002-2006
- Residency in Pediatrics, University of Pittsburgh- UPMC Children's Hospital, 2006-2009
- Fellowship in Pediatric Hematology, University of Pittsburgh- UPMC Children's Hospital, 2009-2012
- Fellowship in Pediatric Blood and Bone Marrow, University of Pittsburgh- UPMC Children's Hospital, 2012-2013
Rosen P, Stenger E, Bochkoris M, Hannon, MJ, Kwoh CK. Family-centered Multidisciplinary Rounds Enhance the Team Approach in Pediatrics. Pediatrics 2009; 123 (4): e603-608. PMID: 19336351.
Stenger EO, Rosborough BR, Mathews LR, Ma H, Mapara MY, Thomson AW and Turnquist HR. IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ-Dependent Apoptosis of Alloreactive CD4+ T Cells and Inhibit Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 2014; 20 (2): 192-201. PMID: 24239650.
Stenger EO, Kazi Z, Lisi E, Gambello MJ, Kishnani P. Immune Tolerance Strategies in Siblings with Infantile Pompe Disease- Advantages for a Preemptive Approach to High-Sustained Antibody Titers. Molecular Genetics and Metabolism Reports 2015; 1 (4): 30-34. PMID: 26167453.
Stenger EO, Chiang KY, Haight A, Qayed M, Kean L, Horan J. Use of Alefacept for Pre-Conditioning in Multiply Transfused Pediatric Patients with Non-Malignant Diseases. Biology of Blood and Marrow Transplantation 2015; 20 (2): 192-201. PMID: 24239650.
Stenger EO, Chinnadurai R, Yuan S, Garcia M, Arafat D, Gibson G, Krishnamurti L, Galipeau J. Bone Marrow Derived Mesenchymal Stromal Cells from Sickle Cell Disease Patients Display Intact Functionality. Biology of Blood and Marrow Transplantation 2017; 23 (5): 736-745. PMID: 28132869.
Heimall J, Logan BR, Cowan MJ, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Pulsipher MA, Parikh S, Martinez C, Kapoor N, O’Reilly R, Boyer M, Pai SY, Goldman F, Burroughs L, Chandra S, Kletzel M, Thakar M, Connelly J, Cuvelier G, Davila B, Shereck E, Knutsen A, Sullivan KE, DeSantes K, Gillio A, Haddad E, Petrovic A, Quigg T, Smith AR, Stenger E, Yin Z, Shearer WT, Buckley RH, Dvorak CC. Immune Reconstitution and Survival of 100 SCID Patients Post Hematopoietic Cell Transplant: A PIDTC Natural History Study. Blood 2017; 130 (25): 2718-2727. PMID: 29021228.
Allen CE, Marsh RA, Dawson P, Bollard C, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano J, Schultz KR, Pai S-Y, Baker KS, Andolina JR, Stenger EO, Connelly JA, Ramirez A, Bryant C, Eapen M, Pulsipher MA. Reduced Intensity Conditioning for Hematopoietic Cell Transplant for HLH and Primary Immune Deficiencies: BMT CTN 1204. Blood 2018; 132 (13): 1438-1451. PMID: 29997222.
Joo SJ, Stenger EO, Yildirim I, Anderson E. Sirolimus-associated Pericardial Effusion with Cardiac Tamponade and Pneumonitis in a Hematopoietic Stem Cell Transplant Recipient. Pediatric Transplantation 2019; 23 (4): e13425. PMID: 31012209.
Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM. Chronic Granulomatous Disease-associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Clinical Immunology 2019; 39 (7): 653-667. PMID: 31376032.
Vander Lugt MT, Chen X, Escolar ML, Carella BA, Barnum JL, Windreich RM, Hill MJ, Poe, MD, Marsh RA, Stanczak H, Stenger EO, Szabolcs P. Reduced-intensity Single-unit Unrelated Cord Blood Transplant with Optional Immune Boost for Non-malignant Disorders. Blood Advances; accepted for publication.